About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 943505, 5 pages
Research Article

Lipoprotein(a) Serum Levels in Diabetic Patients with Retinopathy

1International Ph. D. Program in Neuropharmacology, University of Catania, 95123 Catania, Italy
2Department of Ophthalmology, University of Catania, 95123 Catania, Italy
3Research Center “La Grande Senescenza”, University of Catania, 95125 Catania, Italy

Received 30 April 2013; Accepted 21 May 2013

Academic Editor: Ronald L. Klein

Copyright © 2013 Giulia Malaguarnera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Jung and K. Park, “Posttraumatic bilateral internuclear ophthalmoplegia with exotropia,” Archives of Neurology, vol. 61, no. 3, p. 429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global Prevalence of Diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. H. Kempen, B. J. O'Colmain, M. C. Leske et al., “The prevalence of diabetic retinopathy among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 552–563, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. S. Newfield, M. Polak, R. Marchase, and P. Czernichow, “Epidemiology and genetics of diabetic complications,” Diabetologia, vol. 40, no. 3, pp. B62–B64, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. T. C. Hohman, C. Nishimura, and W. G. Robison Jr., “Aldose reductase and polyol in cultured pericytes of human retinal capillaries,” Experimental Eye Research, vol. 48, no. 1, pp. 55–60, 1989. View at Scopus
  6. E. Duh and L. P. Aiello, “Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox,” Diabetes, vol. 48, no. 10, pp. 1899–1906, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Orchard, “Dyslipoproteinemia and diabetes,” Endocrinology and Metabolism Clinics of North America, vol. 19, no. 2, pp. 361–380, 1990.
  8. M. D. Davis, “Worsening of diabetic retinopathy after improvement of glycemic control,” Archives of Ophthalmology, vol. 116, no. 7, pp. 931–932, 1998. View at Scopus
  9. N. I. Uçgun, Z. Yildirim, N. Kiliç, and E. Gürsel, “The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients,” Annals of the New York Academy of Sciences, vol. 1100, pp. 213–217, 2007. View at Publisher · View at Google Scholar
  10. G. Utermann, H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz, “Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma,” Journal of Clinical Investigation, vol. 80, no. 2, pp. 458–465, 1987. View at Scopus
  11. L. A. Miles, G. M. Fless, E. G. Levin, A. M. Scanu, and E. F. Plow, “A potential basis for the thrombotic risks associated with lipoprotein(a),” Nature, vol. 339, no. 6222, pp. 301–303, 1989. View at Scopus
  12. K. A. Hajjar, D. Gavish, J. L. Breslow, and R. L. Nachman, “Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis,” Nature, vol. 339, no. 6222, pp. 303–305, 1989. View at Scopus
  13. M. Malaguarnera, M. Vacante, C. Russo, et al., “Lipoprotein(a) in cardiovascular diseases,” BioMed Research International, vol. 2013, Article ID 650989, 9 pages, 2013. View at Publisher · View at Google Scholar
  14. M. C. Leske, S. Wu, L. Hyman et al., “Diabetic retinopathy in a black population: the Barbados eye study,” Ophthalmology, vol. 106, no. 10, pp. 1893–1899, 1999. View at Scopus
  15. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Scopus
  16. E. J. Schaefer and J. M. Ordovas, “Metabolism of apolipoproteins A-I, A-II, and A-IV,” Methods in Enzymology, vol. 129, pp. 420–443, 1986. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Ordovas, J. P. Peterson, P. Santaniello, J. S. Cohn, P. W. F. Wilson, and E. J. Schaefer, “Enzyme-linked immunosorbent assay for human plasma apolipoprotein B,” Journal of Lipid Research, vol. 28, no. 10, pp. 1216–1224, 1987. View at Scopus
  18. S. Lenzi, A. Scanu, and R. De Caterina, “Lipoprotein(a) as an athero-thrombotic risk factor: epidemiological evidence and possible pathogenetic mechanisms,” Giornale Italiano di Cardiologia, vol. 26, no. 10, pp. 1203–1225, 1996. View at Scopus
  19. F. Galvano, M. Malaguarnera, M. Vacante et al., “The physiopathology of lipoprotein (a),” Frontiers in Bioscience, vol. 2, pp. 866–875, 2010. View at Scopus
  20. G. Steiner, “Dyslipoproteinemias in diabetes,” Clinical & Investigative Medicine, vol. 18, no. 4, pp. 282–287, 1995.
  21. L. Rampello, I. Vecchio, G. Battaglia, G. Malaguarnera, and L. Rampello, “Diabetic neuropathy. Elements of epidemiology and pathophysiology,” Acta Medica Mediterranea, vol. 28, p. 219, 2012.
  22. R. F. Klein, K. R. Feingold, C. Morgan, W. H. Stern, and M. D. Siperstein, “Relationship of muscle capillary basement membrane thickness and diabetic retinopathy,” Diabetes Care, vol. 10, no. 2, pp. 195–199, 1987. View at Scopus
  23. M. Rodriguez-Fontal, J. B. Kerrison, D. V. Alfaro, and E. P. Jablon, “Metabolic control and diabetic retinopathy,” Current Diabetes Reviews, vol. 5, no. 1, pp. 3–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Calmarza and J. C. Vella, “Lipids, lipoproteins and apolipoprotein (a) isoforms in type 2 diabetic patients,” Journal of Cardiovascular Risk, vol. 6, no. 3, pp. 171–175, 1999. View at Scopus
  25. I. C. Klausen, F. E. Nielsen, L. Hegedus, L. U. Gerdes, P. Charles, and O. Faergeman, “Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a),” Metabolism, vol. 41, no. 8, pp. 911–914, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. L. C. Ramirez, C. Arauz-Pacheco, C. Lackner, G. Albright, B. V. Adams, and P. Raskin, “Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control,” Annals of Internal Medicine, vol. 117, no. 1, pp. 42–47, 1992. View at Scopus
  27. A. Pérez, G. Carreras, A. Caixàs, et al., “Plasma lipoprotein(a) levels are not influenced by glycemic control in type 1 diabetes,” Diabetes Care, vol. 21, no. 9, pp. 1517–1520, 1998.
  28. S. M. Haffner, K. K. Gruber, P. A. Morales et al., “Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study,” American Journal of Epidemiology, vol. 136, no. 9, pp. 1060–1068, 1992. View at Scopus
  29. A. J. Jenkins, J. S. Steele, E. D. Janus, J. D. Santamaria, and J. D. Best, “Plasma apolipoprotein (a) is increased in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria,” Diabetologia, vol. 35, no. 11, pp. 1055–1059, 1992. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Rainwater, J. W. MacCluer, M. P. Stern, J. L. VandeBerg, and S. M. Haffner, “Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size,” Diabetes, vol. 43, no. 7, pp. 942–946, 1994. View at Scopus
  31. M. A. Gall, P. Rossing, E. Hommel et al., “Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 52, no. 6, pp. 513–521, 1992. View at Scopus
  32. M. M. Ritter, M. Loscar, W. O. Richter, and P. Schwandt, “Lipoprotein(a) in diabetes mellitus,” Clinica Chimica Acta, vol. 214, no. 1, pp. 45–54, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. R. E. Maser, C. Laudadio, and G. S. DeCherney, “The effects of age and diabetes mellitus on nerve function,” Journal of the American Geriatrics Society, vol. 41, no. 11, pp. 1202–1204, 1993. View at Scopus
  34. J. M. Taupin, V. Durlach, M. Hassaim et al., “Lipoprotein (a) and diabetes: correlations based on 224 case histories,” Diabete et Metabolisme, vol. 19, no. 2, pp. 250–256, 1993. View at Scopus
  35. M. Maioli, G. Tonolo, A. Pacifico et al., “Raised serum apolipoprotein (a) in active diabetic retinopathy,” Diabetologia, vol. 36, no. 1, pp. 88–90, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Gazzaruso, A. Garzaniti, P. Buscaglia et al., “Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus: relationships to microvascular and neurological complications,” Acta Diabetologica, vol. 35, no. 1, pp. 13–18, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Zhang, B. Chen, and L. Tang, “Metabolic memory: mechanisms and implications for diabetic retinopathy,” Diabetes Research and Clinical Practice, vol. 96, no. 3, pp. 286–293, 2012.
  38. C. H. Kim, H. J. Park, J. Y. Park, S. Hong, Y. Yoon, and K. Lee, “High serum lipoprotein(a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy,” Diabetes Care, vol. 21, no. 12, pp. 2149–2151, 1998. View at Scopus